R. Lucas

C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption.

J. Vacca, S. Gardell, S. D. Lewis, 1998, Bioorganic & medicinal chemistry letters.

Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.

M. Bock, R. Freidinger, J. Vacca, 1997, Journal of medicinal chemistry.

Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site.

R. Freidinger, L. Kuo, Z. Chen, 1997, Journal of medicinal chemistry.

Synthesis and evaluation of the antiproliferative activity of novel isoindolo[2,1-a]quinoxaline and indolo[1,2-a]quinoxaline derivatives

G. Déléris, C. Jarry, D. Thiolat, 2011, Journal of enzyme inhibition and medicinal chemistry.

Synthesis and evaluation of the cytotoxic activity of novel ethyl 4-[4-(4-substitutedpiperidin-1-yl)]benzyl-phenylpyrrolo[1,2-a]quinoxaline-carboxylate derivatives in myeloid and lymphoid leukemia cell lines.

F. Rossi, S. Routier, M. Marchivie, 2016, European journal of medicinal chemistry.

Synthesis and Antiproliferative Effect of Ethyl 4‐[4‐(4‐Substituted Piperidin‐1‐yl)]benzylpyrrolo[1,2‐a]quinoxalinecarboxylate Derivatives on Human Leukemia Cells

Pascal Sonnet, Sandra Rubio, Mathieu Marchivie, 2017, ChemMedChem.